Skip to main content
World Congress on Medical Oncology
Olympic Paris 2024
Test 4
Test 1
Test 2
Test 5
Test 3
Test clone mv
Olympic Paris 2024
Olympic Paris 2024 - VIP - Boss Ticket
Olympic Paris 2024
Finance Code Test
Concrete Institute of Australia’s Biennial National Conference 2025
Concrete Institute of Australia’s Biennial National Conference 2025
Test Goldenowl Conference
Virtual Event 01
Paris Olypmpic Clone 12.09 webinar
7th World Congress of Nanoentomology
NDS NAB Transact testing
JC test 01
Pre-Release 3 Oct
DEX (Digital Employee Experience) conference 2024
test derek
TimeZone Test
TimeZone Test
Talent Events
Event Demo
Olympic Paris 2024 x
original event name for cloning testing
Olympic Paris 2024
Default payment method test
evexus Event - 509
Default payment method test2
Test Worker
Test Worker
charlie test
Arinex 1
NET24 Ho Chi Minh City Workshop 2024
Telefilm 2024 - International Exhibition of Film and Television Technology in Vietnam
Olympic Paris 2024
charlie test 2711
charlie test 2711 cloned
CICM SecurePay testing
The AI Submit 2024
Test webinar 04.12 - - - -
Taylor Swift Clone 04
Taylor Swift Clone 02
Taylor Swift
Taylor Swift Clone
Taylor Swift Clone 01
Import Test
The Trading Summit 2024 (HCM - Vietnam)
Electric Dreams: A Synthwave Extravaganza
Taylor Swift 16
Taylor Swift 12
Taylor Swift 14
Taylor Swift 15
Taylor Swift 17
Taylor Swift 20
Coin Based Hackathon 2024
Rose 01
Import Ticket
Vu Cat Tuong
STEM 1
Kids STEM
CLONE Innovate 2025: A Future Forward Summit
Innovate 2025: A Future Forward Summit
Petals & Sunshine Festival
webinar 05/02
Science
evexus Event - 273
evexus Event - 275
Association webinar 5.2
evexus Event - 274
Aurora Nights 2025 - Webinar
Seoul AI Seminar
Webinar Event - Lily AI - 20/02
evexus Event - 287
Taylor Swift 11
Swifties Only Social Contact
cloned event for Bree QA
evexus Event - 288
evexus Event - 289
Bree QA event
Tim's event
Ralph's event
Tim cloned enable all
Ralph clone event the last one
Hawaii AI Seminar
evexus Event - 293
Tokyo Seminar
Indiana AI Seminar
Registration ticket 2025
TechNova Summit
Event - 28 - 03 - 2025
TechNova Summit [2]
TechNova Summit [3]
Tech v1
Event 28/03/2025
Job Affairs
Fan Job
Webinar Event - Lily AI - 04/03
Event Registration
Association webinar 20.2
Fan's stock query
Registration
Aurora Nights 2025
Ralph test email
Taylor Swift 13
The Core 2025
Rose
The Thirdweb submit
Stress Test Conference 2026
Alan'event
World Congress of Medical Oncology
The AI Seoul Submit 2026
The Core 2026
Times are shown in your local time zone GMT
Recurrent PUJO Ater Paediatric Pyleoplasty: Silent or Symptomatic?
Verbal Presentation

Verbal Presentation

5:00 pm

01 May 2026

Meeting Room M3

RESEARCH PAPERS

Talk Description

Institution: Children's Hospital at Westmead - New South Wales, Australia

Background: Recurrent PUJO after index pyeloplasty is rare and has traditionally been suspected based on symptoms including flank pain and vomiting. However, some children may develop recurrent obstruction and loss of function whilst asymptomatic. The frequency of “silent” recurrent PUJO, and its association with loss of renal function remains poorly defined. Methods: We undertook a 25-year retrospective review of all redo pyeloplasties for recurrent PUJO performed at The Children’s Hospital at Westmead. Cases with concomitant obstructive uropathy or incomplete radiological data were excluded. Symptom status at the time of redo surgery and surveillance USS and MAG3 renography data were analysed. Results: Between 2000 and 2025, twenty children underwent a redo pyeloplasty (85% male, 70% left PUJO). Ten children (50%) were asymptomatic at the time, representing silent recurrent PUJO. The remaining 10 children developed one or more symptoms: significant vomiting (5), recurrent ipsilateral flank pain (4), urosepsis (2), distention with a palpable abdominal mass (2) and new hypertension (1). Four children developed symptoms suggestive of obstruction within 72 hours of stent removal. The median time from pyeloplasty to redo pyeloplasty was 5 months (IQR 3.4 – 11.1), with 80% of redo pyeloplasties occurring within 12 months. Prior to redo pyeloplasty, 88% of children had worsening hydronephrosis (median Δ APD +8.0mm (4.0 – 16.0), and 90% children had a loss of renal function on MAG3 (median Δ DRF -10.5% (-22.5 to -7.5)). Clinically significant loss of renal function (>10%) occurred in 50% of both symptomatic and asymptomatic children. Conclusions: Recurrent PUJO is asymptomatic in 50% of cases and can be associated with loss of renal function. Symptom status alone is not a sufficient discriminator of children at risk of functional decline, and hence, early structured imaging surveillance following pyeloplasty is essential.
Speakers
Contributors
Authors

Dr Georges Tinawi - , Dr Grahame Smith - , Dr Ani Deshpande - , Dr Angus Alexander - , Dr Sarah Giutronich -

Other Suggested Talks
Privacy Statement Header

By confirming your acceptance below, you agree to our Privacy Policy